Molecular characterization of fluoroquinolone resistance in Mycobacterium tuberculosis: Functional analysis of gyrA mutation at position 74

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 2, 2011, Pages 608-614

  Lau, Ricky W T ^a   Ho, Pak Leung ^a   Kao, Richard Y T ^a   Yew, Wing Wai ^b   Lau, Terrence C K ^c   Cheng, Vincent C C ^a   Yuen, Kwok Yung ^a   Tsui, Stephen K W ^c   Chen, Xinchun ^d   Yam, Wing Cheong ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b GRANTHAM HOSPITAL   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d SHENZHEN THIRD PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) A; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; DNA CLEAVAGE; DNA SEQUENCE; DNA SUPERCOILING; DRUG BINDING; DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; IC 50; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPUTUM;

ANTI-INFECTIVE AGENTS; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; TUBERCULOSIS;

EID: 78751697747     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00920-10     Document Type: Article

References (51)

1. Aubry, A., X. S. Pan, L. M. Fisher, V. Jarlier, and E. Cambau. 2004. Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob. Agents Chemother. 48:1281-1288.
2. Aubry, A., et al. 2006. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob. Agents Chemother. 50:104-112.
3. Caminero, J. A. 2008. Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation. Int. J. Tuberc. Lung Dis. 12:869-877.
4. Chan, C. M., et al. 1996. Single-tube nested PCR in the diagnosis of tuberculosis. J. Clin. Pathol. 49:290-294.
5. Chan, R. C., et al. 2007. Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong. J. Antimicrob. Chemother. 59:866-873.
6. Chang, K. C., W. W. Yew, and R. C. Chan. 2010. Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J. Antimicrob. Chemother. 65:1551-1561.
7. Cheng, A. F., et al. 2004. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob. Agents Chemother. 48:596-601.
8. Clinical and Laboratory Standards Institute. 2003. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standards, vol. 23, no. 18. M24-A. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Cole, S. T., et al. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537-544.
10. Cozzarelli, N. R. 1980. DNA gyrase and the supercoiling of DNA. Science 207:953-960.
11. Evans, J., and H. Segal. 2010. Novel multiplex allele-specific PCR assays for the detection of resistance to second-line drugs in Mycobacterium tuberculosis. J. Antimicrob. Chemother. 65:897-900.
12. Giannoni, F., et al. 2005. Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49:2928-2933.
13. Guillemin, I., E. Cambau, and V. Jarlier. 1995. Sequences of conserved region in the A subunit of DNA gyrase from nine species of the genus Mycobacterium: phylogenetic analysis and implication for intrinsic susceptibility to quinolones. Antimicrob. Agents Chemother. 39:2145-2149.
14. Guillemin, I., V. Jarlier, and E. Cambau. 1998. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob. Agents Chemother. 42:2084-2088. (Pubitemid 28363097)
15. Hofmann-Thiel, S., et al. 2009. Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan. Eur. Respir. J. 33:368-374.
16. Jain, A., and P. Dixit. 2008. Multidrug-resistant to extensively drug resistant tuberculosis: what is next? J. Biosci. 33:605-616.
17. Kam, K. M., et al. 2006. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb. Drug Resist. 12:7-11.
18. Karahan, Z. C., and N. Akar. 2005. Restriction endonuclease analysis as a solution for determining rifampin resistance mutations by automated DNA sequencing in heteroresistant Mycobacterium tuberculosis strains. Microb. Drug Resist. 11:137-140.
19. Laponogov, I., et al. 2010. Structural basis of gate-DNA breakage and resealing by type II topoisomerases. PLoS One 5:e11338.
20. Laponogov, I., et al. 2009. Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat. Struct. Mol. Biol. 16:667-669.
21. Lau, R. W., et al. 2010. Rapid diagnosis of multidrug-resistant smear-positive pulmonary tuberculosis. Int. J. Antimicrob. Agents 35:202-203.
22. Leimane, V., et al. 2005. Clinical outcome of individualized treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 365:318-326. (Pubitemid 40139109)
23. Leung, E. T., et al. 2006. Molecular characterization of isoniazid resistance in Mycobacterium tuberculosis: identification of a novel mutation in inhA. Antimicrob. Agents Chemother. 50:1075-1078. (Pubitemid 43328883)
24. Leung, E. T., et al. 2003. Detection of katG Ser315Thr substitution in respiratory specimens from patients with isoniazid-resistant Mycobacterium tuberculosis using PCR-RFLP. J. Clin. Microbiol. 52:999-1003.
25. Lu, T., X. Zhao, and K. Drlica. 1999. Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group. Antimicrob. Agents Chemother. 43:2969-2974.
26. Malik, M., and K. Drlica. 2006. Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol. Antimicrob. Agents Chemother. 50:2842-2844.
27. Malik, M., X. Zhao, and K. Drlica. 2006. Lethal fragmentation of bacterial chromosomes mediated by DNA gyrase and quinolones. Mol. Microbiol. 61:810-825.
28. Migliori, G. B., et al. 2008. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur. Respir. J. 31:1155-1159.
29. Morais Cabral, J. H., et al. 1997. Crystal structure of the breakage-reunion domain of DNA gyrase. Nature 388:903-906.
30. Nolte, F. S., and B. Metchock. 1995. Mycobacterium, p. 400-437. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology. American Society for Microbiology, Washington, DC.
31. Pitaksajjakul, P., et al. 2005. Mutations in the gyrA and gyrB genes of fluoroquinolone-resistant Mycobacterium tuberculosis from TB patients in Thailand. Southeast Asian J. Trop. Med. Public Health 36:228-237.
32. Rinder, H., K. T. Mieskes, and T. Loscher. 2001. Heteroresistance in Mycobacterium tuberculosis. Int. J. Tuber. Lung Dis. 5:339-345.
33. Rodriguez, J. C., M. Ruiz, A. Climent, and G. Royo. 2001. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 17:229-231.
34. Schmidt, B. H., A. B. Burgin, J. E. Deweese, N. Osheroff, and J. M. Berger. 2010. A novel and unified two-metal mechanism for DNA cleavage by type II and IA topoisomerases. Nature 465:641-644.
35. Shi, R., J. Zhang, C. Li, Y. Kazumi, and I. Sugawara. 2006. Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing. J. Clin. Microbiol. 44:4566-4568.
36. Siddiqi, N., et al. 2002. Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from patients in North India. Antimicrob. Agents Chemother. 46:443-450.
37. Somasundaram, S., and N. C. Paramasivan. 2006. Susceptibility of Mycobacterium tuberculosis strains to gatifloxacin and moxifloxacin by different methods. Chemotherapy 52:190-195.
38. Sulochana, S., F. Rahman, and C. N. Paramasivan. 2005. In vitro activity of fluoroquinolones against Mycobacterium tuberculosis. J. Chemother. 17:169-173.
39. Sun, Z., J. Zhang, X. Zhang, S. Wang, Y. Zhang, and C. Li. 2008. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. Int. J. Antimicrob. Agents 31:115-121.
40. Takiff, H. E., et al. 1994. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob. Agents Chemother. 38:773-780.
41. Tretter, E. M., A. J. Schoeffler, S. R. Weisfield, and J. M. Berger. 2010. Crystal structure of the DNA gyrase GyrA N-terminal domain from Mycobacterium tuberculosis. Proteins 78:492-495.
42. van Doorn, H. R., et al. 2008. Fluoroquinolone resistance detection in Mycobacterium tuberculosis with locked nucleic acid probe real-time PCR. Int. J. Tuberc. Lung Dis. 12:736-742.
43. Von Groll, A., et al. 2009. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob. Agents Chemother. 53:4498-4500.
44. Wang, J. Y., et al. 2007. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J. Antimicrob. Chemother. 59:860-865.
45. World Health Organization. 2006. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly. Epidemiol. Rec. 81:430-432.
46. Yam, W. C., K. Y. Yuen, and W. H. Seto. 1998. Direct detection of Mycobacterium tuberculosis in respiratory specimens using an automated DNA amplification assay and a single tube nested polymerase chain reaction (PCR). Clin. Chem. Lab. Med. 36:597-599.
47. Yam, W. C., et al. 2004. Direct detection of rifampin-resistant Mycobacterium tuberculosis in respiratory specimens by PCR-DNA sequencing. J. Clin. Microbiol. 42:4438-4443.
48. Yew, W. W., et al. 2000. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 117:744-751.
49. Yuen, K. Y., W. C. Yam, L. P. Wong, and W. H. Seto. 1997. Comparison of two automated DNA amplification systems with a manual one-tube nested PCR assay for diagnosis of pulmonary tuberculosis. J. Clin. Microbiol. 35:1385-1389.
50. Zhang, Y., and W. W. Yew. 2009. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 13:1320-1330.
51. Zignol, M., et al. 2006. Global incidence of multidrug-resistant tuberculosis. J. Infect. Dis. 194:479-485.